Custom recombinant antibody production using transient CHO expression. Tell us about your antibody format and project requirements to discuss the next steps.
15+
Years of experience
140,000 +
Antibody production runs
25,000 +
Antibodies expressed
4 weeks
From Sequence to Antibody
Custom recombinant antibody expression services – take advantage of more than a decade of experience
With over a decade in recombinant antibody production, evitria has become a trusted partner for clients worldwide. Since 2010, we have performed over 140,000 transfections and purified more than 25,000 antibodies for customers from academic laboratories to global biopharmaceutical companies.
Our custom antibody production range includes:
Afucosylated antibodies
Fc-silenced antibodies
Bispecific antibodies
For early-stage antibody discovery, we offer high-throughput production: parallel CHO expression of up to several hundred constructs per project. Your antibodies are purified and assay-ready within four weeks, with the same analytical package used at clinical scale. No host-cell transitions, no re-optimization, no delays.
We know how tight timelines in biotechnological projects can be. With resources and know-how at hand, our efficient workflow allows us to provide you with recombinant antibodies within only 4 weeks. Starting with a pilot study, large-scale expression commences after 2 weeks, followed by purification, extensive analytics, and – finally – shipment of the deliverables to our customers worldwide.
Week 1
Week 2
Week 3
Week 4
Pilot Study*
Larger-scale expression
Purification
Final analytics
Shipment
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Business days
Explore more insights and resources to support your antibody development
Discovery panel screening (HTP) & in vivo scale-up
Download our comprehensive case study about HTP screening to see how this method and seamless scale-up accelerate early drug discovery.
Our technology spotlight on early Opti-mAb® access for scFv stabilization is about addressing instability, aggregation, and poor expression before they limit manufacturability and lead selection.
Get acces to our case study of a tumor-targeting mAb reformatted into a TAA x CD3 bispecific, with six variants delivered in 4.5 weeks and characterized for binding affinity and thermal stability.
In this technology spotlight we explain how GlymaxX® afucosylation enhances ADCC without amino acid substitutions, using ProBioGen cell engineering with transient CHO expression.
Download the development guide covering batch-consistent glycan profiles, LC-MS verification of modifications such as afucosylation, and high-throughput mass spectrometry for antibody quality control.
Our CHO cell-based expression platform produces recombinant monoclonal antibodies with high purity, exceptional quality, and efficiency. Unlike Escherichia coli and other bacterial expression systems, CHO cells can achieve complex human-like post-translational modifications.
Transient expression of antibody genes in CHO cells also eliminates the need for laboratory animal immunization, resulting in products free from animal contamination and ethical concerns.
This method also enables shorter timelines and higher yields than traditional techniques (e.g. hybridoma technology), delivering fully functional antibodies that meet the rigorous demands of modern research and therapeutic applications.
Studies confirm that with a reliable system, these high-quality, transiently expressed antibodies can meet the necessary standards for clinical evaluation. An early commitment to scalable, reproducible expression methods is key for a successful transition to GMP manufacturing, regulatory approval, and commercial production.
Long-lasting, healthy customer relationships are very
important to us. Anonymity is therefore part of our corporate DNA.
“We have been working with evitria for several years and highly appreciate the high consistency of the delivered material.”
Sr. Scientist, Biotherapeutics, Switzerland
“We have been working with evitria since 2022. We appreciate the openness and flexibility of the team, the high speed and quality of the proteins they deliver.”
Radiopharm Theranostics Ltd.
“We are happy paying for the assured quality that evitria brings.”
Sr Scientist, Biotherapeutics, Series B Startup, Boston
FAQs about our antibody expression service
For the removal of residing reagents, amino acids and other byproducts, protein A purification is standard in biotechnology, and we use alternative resins such as Protein G, L, Kappa/Lambda-Select or anti-IgG-CH1 as needed. An additional size exclusion chromatography (SEC) purification step can be added, as well as ion exchange chromatography. Please inquire for more details
Our average timeline is between 4 and 6 weeks for new antibodies. If we have produced the antibody before then reproduction will take 2.5-3.5 weeks.
We have produced both bispecific and trispecific antibodies in various formats. Please contact your local evitria representative to discuss your specific project.
No, but please see our “Partners” page to find best-in-class solutions for required services. We work together with established partners for optimization of mAb and rAb development workflows.
At evitria, we focus on transient antibody production. Thereby, we rely on CHO cells as our expression system of choice, as they come with several advantages in terms of quality and speed.
No, evitria works with partners to ensure maximum value to customers. For sequencing issues in the production of recombinant antibodies, Rapid Novor is evitria’s partner.
Let’s get in touch with our experts now!
Our team of experts looks forward to answering all your concerns regarding our services and solutions.
